Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Dezember 2019 06:00 ET | Quelle: TransUnion

Canadian Consumer Credit Market Expected to Show Marginal Growth in 2020

TransUnion’s 2020 consumer credit forecast anticipates marginal credit balance growth and broadly stable delinquencies with pockets of stress on certain consumer segmentsAs 2019 draws to a close,...
09. Dezember 2019 05:28 ET | Quelle: Research and Markets

Worldwide Algorithmic Trading Markets to 2024 - Lucrative Opportunities in Cloud-based Algorithmic Trading Platforms

Dublin, Dec. 09, 2019 (GLOBE NEWSWIRE) -- The "Global Algorithmic Trading Market: Growth, Trends, and Forecasts (2019-2024)" report has been added to ResearchAndMarkets.com's offering.The...
09. Dezember 2019 03:38 ET | Quelle: Research and Markets

U.S. Grocery Market Focus on the Amazon Food Shopper, 2019 Edition

Dublin, Dec. 09, 2019 (GLOBE NEWSWIRE) -- The "U.S. Grocery Market Focus: The Amazon Food Shopper, 2nd Edition" report has been added to ResearchAndMarkets.com's offering. This...
08. Dezember 2019 10:39 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In...
08. Dezember 2019 09:00 ET | Quelle: Karyopharm Therapeutics Inc.

Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting

-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with...
08. Dezember 2019 07:30 ET | Quelle: F. Hoffmann-La Roche Ltd

New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia

In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia...
07. Dezember 2019 08:40 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or...
06. Dezember 2019 16:06 ET | Quelle: Oil-Dri Corporation Of America

Oil-Dri Announces First Quarter of Fiscal 2020 Results

CHICAGO, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced its first quarter fiscal 2020 earnings....
06. Dezember 2019 08:45 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Xenon’s Epilepsy Programs Continue to Advance Including Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans for Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in...
06. Dezember 2019 07:30 ET | Quelle: Onconova Therapeutics, Inc.

Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel...

Vorherige Seite

Nächste Seite